Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSEMAP lesion dosimetry-response study in bone metastases during standard [177Lu]Lu-PSMA therapy
NL-OMON61521Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan and lutetium Lu 177 PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University Medical Center Groningen. Primary endpoints: Relationship between lesion absorbed radiation dose and lesion response, Minimum lesion radiation dose for measurable response and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetanlutetium Lu 177 PSMA I&T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON61521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61521.